Supernus Pharmaceuticals Sales Y/Y

Sales Y/Y of Supernus Pharmaceuticals, Inc.

52.46%
Annual revenue growth for past 3 years is the revenue growth from one year to the next averaged over the last 3 years.

The annual revenue growth is calculated as is an arithmetic mean of a series of growth rates. For this specific metric the calculation takes into account a series of the last three annual growth rates. The average annual revenue growth is useful for determining trends but it can be misleading since only the differences between years are compared and not the starting and ending point (which can happen to be identical). As a result, compounded annual growth rate can be used for evaluating changing financial metrics.


About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy. The company's product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder (ADHD); and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD. It also develops SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression. The company markets its products through wholesalers and pharmaceutical distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.

Companies with profit margin similar to Supernus Pharmaceuticals